View details of this raise on Seedstage

Fort Worth, TX

Developing an oral therapy for APC-mutant colorectal cancer.

• Targeted Therapy: BT-1501 is designed to target APC-mutant colorectal cancer, addressing a large patient population.
• Significant Funding: The company has secured $17 million in non-dilutive funding from CPRIT and support from the American Cancer Society.
• Experienced Leadership: The management team has over 150 years of combined experience in biopharmaceutical development.
• Preclinical Progress: BT-1501 has shown promising results in preclinical models, reducing tumor growth significantly.
• Future Expansion: Plans to expand the TASIN platform to other oncology and neurology indications.

Barricade Therapeutics is developing BT-1501, an oral investigational therapy targeting APC-mutant colorectal cancer, a mutation present in approximately 80% of colorectal cancer (CRC) patients. The company is advancing its lead candidate, BT-1501, which is designed to inhibit Emopamil Binding Protein (EBP) in APC-mutant tumor cells, exploiting a specific vulnerability in these cancer cells. This approach aims to address a significant unmet need in the CRC treatment landscape, particularly for patients who do not respond to existing therapies. Barricade Therapeutics has secured $17 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and additional support from the American Cancer Society’s BrightEdge Fund, positioning the company to initiate first-in-human studies.

The company is led by a management team with extensive experience in biopharmaceutical development, including multiple FDA submissions. Barricade Therapeutics is preparing for a Phase 1 clinical trial of BT-1501, anticipated to start in 2026, subject to regulatory clearance and funding availability. The company’s strategy includes expanding its TASIN platform to target other oncology indications, such as neuroblastoma and hepatocellular carcinoma, and exploring potential applications in neurology. Barricade Therapeutics holds global rights to its TASIN/EBP inhibitor compound portfolio, with intellectual property protection extending through 2039.

Company Info

Barricade Therapeutics is developing BT-1501, an oral therapy targeting APC-mutant colorectal cancer, aiming to address a significant patient population.

Barricade Therapeutics is a biotechnology company focused on developing innovative therapies for colorectal cancer, particularly targeting APC-mutant tumors. Their lead investigational drug, BT-1501, is an oral therapy designed to address the specific vulnerabilities of APC-mutant colorectal cancer, which is present in approximately 80% of CRC patients. The company is currently in the preclinical stage, with plans to initiate Phase 1 clinical trials in 2026, subject to regulatory approval and funding.

The company has secured significant non-dilutive funding from the Cancer Prevention & Research Institute of Texas and support from the American Cancer Society. Barricade aims to address a large and underserved patient population with its targeted approach, leveraging its TASIN platform to potentially expand into other oncology and neurology indications. The management team brings extensive experience in drug development, positioning Barricade to advance its investigational therapies through the clinical pipeline.